187 related articles for article (PubMed ID: 20564318)
1. Contribution of HPC1 (RNASEL) and HPCX variants to prostate cancer in a founder population.
Agalliu I; Leanza SM; Smith L; Trent JM; Carpten JD; Bailey-Wilson JE; Burk RD
Prostate; 2010 Nov; 70(15):1716-27. PubMed ID: 20564318
[TBL] [Abstract][Full Text] [Related]
2. Association of HPC2/ELAC2 and RNASEL non-synonymous variants with prostate cancer risk in African American familial and sporadic cases.
Robbins CM; Hernandez W; Ahaghotu C; Bennett J; Hoke G; Mason T; Pettaway CA; Vijayakumar S; Weinrich S; Furbert-Harris P; Dunston G; Powell IJ; Carpten JD; Kittles RA
Prostate; 2008 Dec; 68(16):1790-7. PubMed ID: 18767027
[TBL] [Abstract][Full Text] [Related]
3. Genetic variation in RNASEL and risk for prostate cancer in a population-based case-control study.
Fesinmeyer MD; Kwon EM; Fu R; Ostrander EA; Stanford JL
Prostate; 2011 Oct; 71(14):1538-47. PubMed ID: 21360564
[TBL] [Abstract][Full Text] [Related]
4. RNASEL mutation screening and association study in Ashkenazi and non-Ashkenazi prostate cancer patients.
Orr-Urtreger A; Bar-Shira A; Bercovich D; Matarasso N; Rozovsky U; Rosner S; Soloviov S; Rennert G; Kadouri L; Hubert A; Rennert H; Matzkin H
Cancer Epidemiol Biomarkers Prev; 2006 Mar; 15(3):474-9. PubMed ID: 16537704
[TBL] [Abstract][Full Text] [Related]
5. A major locus for hereditary prostate cancer in Finland: localization by linkage disequilibrium of a haplotype in the HPCX region.
Baffoe-Bonnie AB; Smith JR; Stephan DA; Schleutker J; Carpten JD; Kainu T; Gillanders EM; Matikainen M; Teslovich TM; Tammela T; Sood R; Balshem AM; Scarborough SD; Xu J; Isaacs WB; Trent JM; Kallioniemi OP; Bailey-Wilson JE
Hum Genet; 2005 Aug; 117(4):307-16. PubMed ID: 15906096
[TBL] [Abstract][Full Text] [Related]
6. Mutation screening and association study of RNASEL as a prostate cancer susceptibility gene.
Maier C; Haeusler J; Herkommer K; Vesovic Z; Hoegel J; Vogel W; Paiss T
Br J Cancer; 2005 Mar; 92(6):1159-64. PubMed ID: 15714208
[TBL] [Abstract][Full Text] [Related]
7. Genetic analysis of the RNASEL gene in hereditary, familial, and sporadic prostate cancer.
Wiklund F; Jonsson BA; Brookes AJ; Strömqvist L; Adolfsson J; Emanuelsson M; Adami HO; Augustsson-Bälter K; Grönberg H
Clin Cancer Res; 2004 Nov; 10(21):7150-6. PubMed ID: 15534086
[TBL] [Abstract][Full Text] [Related]
8. A genetic epidemiological study of hereditary prostate cancer (HPC) in Finland: frequent HPCX linkage in families with late-onset disease.
Schleutker J; Matikainen M; Smith J; Koivisto P; Baffoe-Bonnie A; Kainu T; Gillanders E; Sankila R; Pukkala E; Carpten J; Stephan D; Tammela T; Brownstein M; Bailey-Wilson J; Trent J; Kallioniemi OP
Clin Cancer Res; 2000 Dec; 6(12):4810-5. PubMed ID: 11156239
[TBL] [Abstract][Full Text] [Related]
9. The RNASEL 471delAAAG allele and prostate cancer in Ashkenazi Jewish men.
Kotar K; Hamel N; Thiffault I; Foulkes WD
J Med Genet; 2003 Mar; 40(3):e22. PubMed ID: 12624151
[No Abstract] [Full Text] [Related]
10. Role of genetic polymorphisms of the RNASEL gene on familial prostate cancer risk in a Japanese population.
Nakazato H; Suzuki K; Matsui H; Ohtake N; Nakata S; Yamanaka H
Br J Cancer; 2003 Aug; 89(4):691-6. PubMed ID: 12915880
[TBL] [Abstract][Full Text] [Related]
11. Association of RNASEL variants with prostate cancer risk in Hispanic Caucasians and African Americans.
Shook SJ; Beuten J; Torkko KC; Johnson-Pais TL; Troyer DA; Thompson IM; Leach RJ
Clin Cancer Res; 2007 Oct; 13(19):5959-64. PubMed ID: 17908993
[TBL] [Abstract][Full Text] [Related]
12. Genetic variation in RNASEL associated with prostate cancer risk and progression.
Meyer MS; Penney KL; Stark JR; Schumacher FR; Sesso HD; Loda M; Fiorentino M; Finn S; Flavin RJ; Kurth T; Price AL; Giovannucci EL; Fall K; Stampfer MJ; Ma J; Mucci LA
Carcinogenesis; 2010 Sep; 31(9):1597-603. PubMed ID: 20576793
[TBL] [Abstract][Full Text] [Related]
13. Arg462Gln sequence variation in the prostate-cancer-susceptibility gene RNASEL and age of onset of hereditary non-polyposis colorectal cancer: a case-control study.
Krüger S; Silber AS; Engel C; Görgens H; Mangold E; Pagenstecher C; Holinski-Feder E; von Knebel Doeberitz M; Moeslein G; Dietmaier W; Stemmler S; Friedl W; Rüschoff J; Schackert HK;
Lancet Oncol; 2005 Aug; 6(8):566-72. PubMed ID: 16054567
[TBL] [Abstract][Full Text] [Related]
14. Mutational analysis of susceptibility genes RNASEL/HPC1, ELAC2/HPC2, and MSR1 in sporadic prostate cancer.
Nupponen NN; Wallén MJ; Ponciano D; Robbins CM; Tammela TL; Vessella RL; Carpten JD; Visakorpi T
Genes Chromosomes Cancer; 2004 Feb; 39(2):119-25. PubMed ID: 14695991
[TBL] [Abstract][Full Text] [Related]
15. A novel founder mutation in the RNASEL gene, 471delAAAG, is associated with prostate cancer in Ashkenazi Jews.
Rennert H; Bercovich D; Hubert A; Abeliovich D; Rozovsky U; Bar-Shira A; Soloviov S; Schreiber L; Matzkin H; Rennert G; Kadouri L; Peretz T; Yaron Y; Orr-Urtreger A
Am J Hum Genet; 2002 Oct; 71(4):981-4. PubMed ID: 12145743
[TBL] [Abstract][Full Text] [Related]
16. Association of susceptibility alleles in ELAC2/HPC2, RNASEL/HPC1, and MSR1 with prostate cancer severity in European American and African American men.
Rennert H; Zeigler-Johnson CM; Addya K; Finley MJ; Walker AH; Spangler E; Leonard DG; Wein A; Malkowicz SB; Rebbeck TR
Cancer Epidemiol Biomarkers Prev; 2005 Apr; 14(4):949-57. PubMed ID: 15824169
[TBL] [Abstract][Full Text] [Related]
17. Association between RNASEL, MSR1, and ELAC2 single nucleotide polymorphisms and gene expression in prostate cancer risk.
Alvarez-Cubero MJ; Pascual-Geler M; Martinez-Gonzalez LJ; Expósito Ruiz M; Saiz M; Cozar JM; Lorente JA
Urol Oncol; 2016 Oct; 34(10):431.e1-8. PubMed ID: 27318894
[TBL] [Abstract][Full Text] [Related]
18. [G138A polymorphism of the RNASEL gene and its association with the development of prostate cancer. Preliminary study].
Zabala W; Delgado C; Pardo T; Borjas L; Rojas-Atencio A; Reyes F; Quintero JM
Invest Clin; 2009 Sep; 50(3):295-301. PubMed ID: 19961052
[TBL] [Abstract][Full Text] [Related]
19. Single and multivariate associations of MSR1, ELAC2, and RNASEL with prostate cancer in an ethnic diverse cohort of men.
Beuten J; Gelfond JA; Franke JL; Shook S; Johnson-Pais TL; Thompson IM; Leach RJ
Cancer Epidemiol Biomarkers Prev; 2010 Feb; 19(2):588-99. PubMed ID: 20086112
[TBL] [Abstract][Full Text] [Related]
20. Pathological aggressiveness of prostatic carcinomas related to RNASEL R462Q allelic variants.
Larson BT; Magi-Galluzzi C; Casey G; Plummer SJ; Silverman R; Klein EA
J Urol; 2008 Apr; 179(4):1344-8. PubMed ID: 18289577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
